CTRI/2020/11/029176招募中4 期
A prospective multicenter randomized open label active controlled study to assess effect of Remogliflozin on biomarkers of heart failure compared to Empagliflozin in patients of type 2 diabetes mellitus with chronic heart failure. - REMIT-HF
Sengupta Hospital and Research Institute0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adults (ââ?°Â¥ 18 years) of either gender diagnosed with Type-2 Diabetes Mellitus more than 6 months back
- •2. Having uncontrolled glycaemia (HbA1c >6.5 & <9.0%) with no change in anti-diabetic treatment therapy since last 8 weeks
- •3. With comorbid Chronic heart failure diagnosed at least 3 months prior to screening & in NYHA HF Class I to III during screening) without change in NYHA functional classification prior to randomization
- •4. Having reported reduced EF (defined as LVEF <40%) as per local reading (obtained under stable condition by echocardiography, radionuclide ventriculography, invasive angiography, MRI or CT) measured within 6 months from the screening visit.
- •5. Having elevated NT-proBNP levels >600 pg/mL (or >1200 pg/mL in patients with AF) analysed at central Appropriate dose of medical therapy (such as ACEi, ARB, Ã?²-blocker, oral diuretics, MRA, ARNI, ivabradine) and/or appropriate device therapy, consistent with prevailing CV guidelines & local practice, stable for at least 3 week prior to Visit 1(screening) and during screening period until Visit 2 (Randomisation) with the exception of diuretics stable for only one week prior to Visit 2 to control symptoms.
- •6. Patients who understand & willing to comply with study requirements and provide written informed consent for participation
排除标准
- •1. Patients who are being treated or have been treated with SGLT2i in past 12 weeks
- •2. Patients with evidence of Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA in past 12 weeks prior
- •3. Heart transplant recipient, or listed for heart transplant implanted left ventricular assist device (LVAD) at screening
- •4. Cardiomyopathy based on infiltrative diseases (e.g. amyloidosis), accumulation diseases (e.g. haemochromatosis, Fabry disease), muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), hypertrophic obstructive cardiomyopathy, induced by chemotherapy or peripartum or known pericardial constriction
- •5. Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial in the investigatorââ?¬•s opinion
- •6. Acute decompensated HF (exacerbation of chronic HF) requiring IV diuretics, IV, inotropes, or i.v. vasodilators, or LVAD within 1 week from discharge to Visit 1 (Screening) and during screening period until Visit 2 (Randomisation)
- •7. Atrial fibrillation or atrial flutter with a resting heart rate >110 bpm documented by ECG at Visit 1(Screening)
- •8. Untreated ventricular arrhythmia with syncope in patients without ICD documented within the 3 months prior to Visit 1
- •9. Implanted cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) within 3 months prior to Visit 1, or if there is an intent to implant ICD or CRT within 6 months of visit 2
- •10. Symptomatic bradycardia or second or third degree heart block without a pacemaker after adjusting beta-blocker therapy, if appropriate
- •11. Systolic blood pressure (SBP) ââ?°Â¥ 180 mmHg at Visit 2. If SBP >150mmHg and <180mmHg at Visit 2, the patient should be receiving at least 3 antihypertensive drugs
- •12. Symptomatic hypotension and/or a SBP < 100 mmHg at Visit 1 or Visit 2
- •13. Type 1 diabetes mellitus
- •14. History of diabetic ketoacidosis, diabetic coma, or hypoglycemic attack ââ?°Â¤6 months prior to screening
- •15. Patients with eGFR <60 ml/min/1.73 m2
- •16. Patients with severe organ system disorders viz. Hepatic, Renal, Neoplastic, Neurological or Psychiatric disorders.
- •17. Patients with planned surgery in next 24 weeks or has undergone major operative procedure in past 3 months
- •18. CHF (NYHA functional classification IV)
- •19. Patients with pituitary or adrenal dysfunction
- •20. Patients with malnutrition, starvation, irregular eating pattern, lack of dietary intake, or debilitation or with a gastrointestinal disorder, such as diarrhea or vomiting, or Gastrointestinal surgery that could interfere with trial medication absorption in the investigatorââ?¬•s opinion
- •21. Patients with low or high body weight (BMI <18.5 kg/m2 or >45 kg/m2)
- •22. History of hypersensitivity to ingredients of SGLT2 inhibitors
- •23. Pregnant or suspected pregnancy in females, Lactating females & Patients of child bearing potential not willing to use effective non-hormonal method of contraception
- •24. Patients with severe infection or trauma at trial screening
- •25. Considered inappropriate for the study by investigators due to other reasons
研究者
相似试验
已完成
2 期
Biological E’s Polio vaccine clinical study for protection against Polio disease in 6-8 weeks old infants.CTRI/2023/08/055993Biological E.Limited120
进行中（未招募）
3 期
Efficacy and safety of masitinib to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanomaCTRI/2014/10/005095AB Science
招募中
不适用
A study comparing oral hydroxychloroquine and supportive treatment with supportive treatment alone for management of IgA nephropathyCTRI/2021/07/034929one
Unknown
3 期
A prospective open label, randomized, multi-centre, parallel design, controlled study to evaluate the efficacy and safety of DNANOPAURONA to treating castration resistant prostate cancerCTRI/2018/05/013553Dhanvantari Nano Ayushadi Private Limited
进行中（未招募）
1 期
A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus Variable dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patients with refractory diabetic macular oedema.EUCTR2012-003661-17-GBMoorfields Eye Hospital NHS Foundation Trust100